SCHEMBL5453258

SCHEMBL5453258

NC(=O)c1c(NC(=O)C=Cc2ccccc2)sc2c1CCOC2

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 7/20 0.73
MAPT P10636 6/20 0.60
NPC1 O15118 4/20 0.60
RAB9A P51151 4/20 0.60
NPSR1 Q6W5P4 1/20 0.60
CFTR P13569 1/20 0.57
LMNA P02545 1/20 0.56
TP53 P04637 1/20 0.56
RAB7A P51149 1/20 0.50
PTPRC P08575 1/20 0.49
PTPN2 P17706 1/20 0.49
PTPN1 P18031 1/20 0.49
PTPRB P23467 1/20 0.49
PTPRE P23469 1/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
CASP3 P42574 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
CXCR2 P25025 1/20 0.46
CNR2 P34972 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453252 1.00 FLT3 (0.73) FLT3MAPTNPC1RAB9ANPSR1
SCHEMBL5455833 0.84 FLT3 (1.00) FLT3MAPTNPC1RAB9ANPSR1
SCHEMBL5455830 0.84 FLT3 (1.00) FLT3MAPTNPC1RAB9ANPSR1
SCHEMBL5462689 0.84 CFTR (0.57) FLT3MAPTRAB9ACFTRRAB7A
SCHEMBL5462693 0.84 CFTR (0.57) FLT3MAPTRAB9ACFTRRAB7A
SCHEMBL5449633 0.82 CFTR (0.60) FLT3MAPTRAB9ACFTRPTPRC
SCHEMBL5449628 0.82 CFTR (0.60) FLT3MAPTRAB9ACFTRPTPRC
SCHEMBL5455947 0.80 MEN1 (0.65) FLT3MAPTNPC1RAB9ACFTR
SCHEMBL5458508 0.78 CFTR (0.61) FLT3MAPTRAB9ACFTRPTPRC
SCHEMBL5451008 0.78 CFTR (0.59) FLT3MAPTNPC1RAB9ACFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885MAPT 21/4885NPC1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.